Guardant Health (NASDAQ:GH) Issues Quarterly Earnings Results

Guardant Health (NASDAQ:GH) posted its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.25, Briefing.com reports. The firm had revenue of $60.85 million for the quarter, compared to analysts’ expectations of $45.40 million. Guardant Health had a negative return on equity of 22.93% and a negative net margin of 60.08%. The company’s quarterly revenue was up 180.4% compared to the same quarter last year. During the same quarter last year, the business earned ($1.94) EPS.

GH stock traded up $7.69 during trading hours on Friday, hitting $71.89. 3,794,600 shares of the stock were exchanged, compared to its average volume of 1,093,573. The company has a 50-day simple moving average of $66.52 and a two-hundred day simple moving average of $80.32. Guardant Health has a 12 month low of $31.06 and a 12 month high of $112.21. The firm has a market capitalization of $6.32 billion and a P/E ratio of -25.68.

Several research analysts have weighed in on the company. Canaccord Genuity reiterated a “buy” rating and set a $125.00 price objective on shares of Guardant Health in a research report on Friday. Zacks Investment Research cut Guardant Health from a “buy” rating to a “hold” rating in a research report on Thursday. JPMorgan Chase & Co. increased their price objective on Guardant Health from $90.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Cowen set a $110.00 price objective on Guardant Health and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, ValuEngine upgraded Guardant Health from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $104.40.

In other news, insider Richard B. Lanman sold 5,764 shares of Guardant Health stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $67.99, for a total transaction of $391,894.36. Also, Chairman Amirali Talasaz sold 100,000 shares of Guardant Health stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $100.17, for a total value of $10,017,000.00. The disclosure for this sale can be found here. Insiders have sold 5,883,465 shares of company stock worth $474,143,453 over the last three months. Insiders own 13.00% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

Featured Article: What is the yield curve?

Earnings History for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit